Early access to Santhera’s DMD therapy Raxone extended in the UK
UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAM...
read more